Please be kindly noted that our product can only be used for research to organizations or companies and we don't cooperate with personal buyers.
Application: Ibrutinib is a small-molecule inhibitor of BTK for the treatment of hematologic tumors such as mantle cell lymphoma (MCL), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), and Warf's macroglobulinemia (WM).
Ibrutinib is an BTK inhibitor that forms a covalent bond with a cysteine residue in the active site of BTK (Cys481), leading to its inhibition. The inhibition of BTK plays a role in the B-cell receptor signaling and thus, the presence of ibrutinib prevents the phosphorylation of downstream substrates such as PLC-γ.
Huateng Pharma. can provide Ibrutinib (CAS NO.936563-96-1 )from milligram to kilogram or even tons scale. Contact us at firstname.lastname@example.org for more details.
I want to comment